Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
glp-1 obesity drug news today oct 2025 21 Weight Loss Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap GLP-1 Weight-Loss Drug retatrutide phase 2 trial Electrolyte+ Flavour:Pineapple Punch spreadr-hidden
retatrutide phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist ( GLP1, GIP, glucagon), just released
GLP-1 agonists include Liraglutide (Victoza), subcutaneous Semaglutide (Ozempic), Tirzepatide (Wegovy) and Dulaglutide (Trulicity)
spreadr-hidden
Electrolyte+ Flavour:Pineapple Punch
Medications known as glucagon-like peptide-1 receptor (GLP-1) agonists continue to rise in popularity thanks to their ability to help manage blood sugar levels and reduce hunger and food intake, thus potentially supporting weight loss
:max_bytes(150000):strip_icc():focal(749x0:751x2)/Kelly-Clarkson-sirius-tout-110823-96155c0ddb8d4397bccc90c7dc86bee1.jpg)
